Early and Advanced Triple Negative Breast Cancer (TNBC)

Authored by Ilana Schlam, published on 2026-08-24 22:33:05.0

The algorithm is broadly aligned with contemporary TNBC practice: neoadjuvant pembrolizumab plus chemotherapy for high-risk early TNBC; adjuvant escalation strategies for residual disease including capecitabine and olaparib for germline BRCA carriers; and first-line PD-L1–directed immunochemotherapy in metastatic disease. It appropriately flags key evidence gaps (e.g., combining/sequence of pembrolizumab with capecitabine/olaparib; ADC sequencing; limited TNBC subset data for HER2-low T-DXd). The advanced-disease ADC-in-1L components (SG±pembro; dato-DXd) are evolving and guideline adoption may vary by region and regulatory status.

  1. Early stage TNBC
    This is a framing node; guidelines are most applicable to support overall staging-based treatment principles (surgery ± radiation, neoadjuvant therapy for higher-risk disease, and post-neoadjuvant escalation for residual disease).
    • <2 cm and node negative
      • < 1 cm
        • Surgery
          • Observation (T1a) vs chemotherapy
            • Radiotherapy if indicated
              Radiation is indicated for some with early stage disease.
              • Postmenopausal?
                Add Zometa for postmenopausal patients, q6 months for 2-3 years (Early stage)
      • 1-2 cm
        • Surgery
          • Chemotherapy
            For 1–2 cm node-negative TNBC, adjuvant chemotherapy is generally recommended; neoadjuvant chemotherapy is an option to assess response and guide escalation, but immunotherapy is typically reserved for higher-risk tumors in many guidelines.
            • Radiotherapy if indicated
              Radiation is indicated for some with early stage disease.
              • Postmenopausal?
                Add Zometa for postmenopausal patients, q6 months for 2-3 years (Early stage)
    • ≥2 cm or node positive
      • TC-AC + pembro (Keynote 522 Preferred for high risk)
        Keynote 522 preferred for high risk Can consider carbo/docetaxel/pembro per NeoPACT if not eligible for anthracyclines
        • Surgery
          • pCR
            • Radiotherapy if indicated
              Radiation is indicated for some with early stage disease.
              • Pembro Keynote 522
                Continuation of adjuvant pembrolizumab after surgery is part of the KEYNOTE-522 regimen irrespective of pCR status and is supported by event-free and overall survival improvements.
          • RD*
            *Keynote 522 studied adjuvant pembro irrespective of RD vs pCR, no clear data about combination of pembro + capecitabine. Olaparib showed improvements in outcomes in BRCA carriers with RD
            • Radiotherapy if indicated
              Radiation is indicated for some with early stage disease.
              • Pembro + ?Capecitabine (BRCAwt) (Keynote 522, CreateX)
                Capecitabine for residual disease after neoadjuvant chemotherapy in TNBC is supported by CREATE-X, but KEYNOTE-522 did not establish the safety/efficacy of concurrent pembrolizumab plus capecitabine; this combination remains extrapolative and practice-variable.
              • Pembro + ?Olaparib g(BRCA) (Keynote 522, OLYMPIA)
                Adjuvant olaparib for high-risk, gBRCA1/2 early HER2-negative breast cancer is supported by OlympiA, and pembrolizumab continuation is supported by KEYNOTE-522; however, concurrent use/optimal sequencing of olaparib with adjuvant pembrolizumab after residual disease is not established by randomized data.
  2. Advanced TNBC
    • PDL1 + (22C3 CPS >10)
      *ASCENT 04: Saci+pembro vs chemo+pemrbo improved PFS (PDL1+) +crossover
      • Pembro + SG (ASCENT 04)
        vs Pembro + chemo Keynote 355
        • gBRCA 1/2 mutation
          • PARPi (ola, tala) (OLYMPIAD, EMBRACA)
            PARP inhibitors are supported for germline BRCA1/2-mutated, HER2-negative advanced breast cancer based on pivotal randomized trials demonstrating improved PFS versus chemotherapy.
            • HER2 1-2+
              • Chemotherapy
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
            • HER2 low
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
            • HER2 0
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
        • No gBRCA 1/2mutation
          • Chemotherapy
            • HER2 1-2+
              • Chemotherapy
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
            • HER2 low
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
            • HER2 0
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
    • PDL1 -
      • Dato-DXd vs SG (ASCENT 05, TROPION BREAST 02)
        Standard first-line treatment for PD-L1–negative metastatic TNBC has historically been chemotherapy; ADC use earlier in the course is rapidly evolving. The cited ASCENT-03 and TROPION-Breast02 are important but their incorporation depends on publication status, magnitude of benefit, and approvals.
        • gBRCA 1/2 mutation
          • PARPi (ola, tala) (OLYMPIAD, EMBRACA)
            PARP inhibitors are supported for germline BRCA1/2-mutated, HER2-negative advanced breast cancer based on pivotal randomized trials demonstrating improved PFS versus chemotherapy.
            • HER2 1-2+
              • Chemotherapy
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
            • HER2 low
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
            • HER2 0
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
        • No gBRCA 1/2mutation
          • Chemotherapy
            • HER2 1-2+
              • Chemotherapy
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
            • HER2 low
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • T-DXd** DESTINY-Breast04 (After 1+ line)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
            • HER2 0
              • Sacituzumab-govitecan** ASCENT (After 2+ lines)
                ** 1L Dato-DD vs SG in PDL1-, choose based on patient preference, toxicity profile, schedule, etc. No data about ADC sequencing.
              • Chemotherapy
tosprivacyOverall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerClinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer NeoPACT Phase 2 Clinical TrialAdjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerSacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerStudy of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/​PD-L1 Inhibitor Therapy (TROPION-Breast02)OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerTalazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerFinal Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression